Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and cilofexor/firsocostat in NASH cirrhosis
NCT04971785Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2021
- Primary completion
- Nov 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of semaglutide, cilofexor and firsocostat in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Gilead Sciences. Primary endpoint: ≥1-stage improvement in fibrosis without worsening of NASH at 72 weeks. Started Aug 2021; status: completed.
02
Drugs
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04971785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971785.